Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 86-92

  Lopez, Massimo ^a   Vici, Patrizia ^a   Di Lauro, Luigi ^a   Conti, Francesca ^a   Paoletti, Giancarlo ^a   Ferraironi, Alessandro ^a   Sciuto, Rosa ^a   Giannarelli, Diana ^a   Maini, Carlo Ludovico ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIRUBICIN; RAZOXANE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEART PROTECTION; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0031983153     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.86     Document Type: Article

References (34)

1. Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drugs. N Engl J Med 305:153-159, 1981
2. Bastholt L, Dalmark M, Gjedde S, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996
3. Jones RB, Holland JF, Bhardwaj S, et al: A phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987
4. O'Brian RM, Baker LH, Gottilials JE, et al: Dose response evaluation of Adriamycin in human neoplasia. Cancer 39:1940-1947, 1977
5. Pinedo HM, Bramwell VHC, Mouridsen MD, et al: Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 53:1825-1832, 1984
6. Myers CE, McGuire WP, Liss RH, et al: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167, 1977
7. Breed JG, Zimmerman AN, Dormans JA, et al: Failure of the antioxidant vitamin E to protect against Adriamycin-induced cardiotoxicity in the rabbit. Cancer Res 40:2033-2038, 1980
8. Myers CE, Bonow R, Palmeri S, et al: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetyl-cysteine. Semin Oncol 10:53-55, 1983
9. Hortobagyi GN, Frye D, Buzdar AV, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast cancer. Cancer 63:37-45, 1989
10. Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979
11. Carriò I, Lopez-Pousa A, Estorch M, et al: Detection of doxorubicin cardiotoxicity in patients with sarcomas by Indium-111-antimyosin monoclonal antibody studies. J Nucl Med 34:1503-1507. 1993
12. Dey HA, Kassamali H: Radionuclide evaluation of doxorubicin cardiotoxicity: The need for caution interpretation. Clin Nucl Med 13:565-568, 1985
13. Carriò I, Estorch M, Berna L, et al: Assessment of anthracycline-induced myocardial damage by quantitative indium-111 myosinspecific monoclonal antibody studies. Eur J Nucl Med 18:806-812, 1991
14. Estorch M, Carriò I, Martinez-Duncker D, et al: Myocyte cell damage after administration of doxorubicin of mitoxantrone in breast cancer patients assessed by indium-111 antimyosin monoclonal antibody studies. J Clin Oncol 11:1264-1268, 1993
15. Lekakis J, Vassilopoulus N, Psichoyiou H, et al: Doxorubicin cardiotoxicity detected by indium-111 myosin-specific imaging. Eur J Nucl Med 18:225-226, 1991
16. Hasinoff BB: The interaction of the cardioprotective agent ICRF-187; Its hydrolysis product (ICRF-198) and other chelating agents with Fe (III) and Cu (II) complexes of Adriamycin. Agents Act 26:378-385, 1989
17. Herman EH, Ferrans VJ: Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest 49:69-77, 1983
18. Woodman RJ, Cysyk RL, Kline I, et al: Enhancement of the effectiveness of daunorubicin or Adriamycin against early mouse L1210 leukemia with ICRF-187. Cancer Chemother Rep 59:689-695, 1975
19. Herman EH, Ferrans VJ: Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with ICRF-187. Cancer Res 41:3436-3440, 1981
20. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
21. Wexler LH, Andrich MP, Venzon D, et al: A phase II trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372, 1996
22. Kolaric K, Bradamonte V, Cervek J, et al: A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology 52:251-255, 1995
23. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (ed 8). Boston, MA, Little Brown, 1979
24. Basser R, Green M: Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 19:57-77, 1993
25. Hryniuk WM, Levine MN, Levin L: Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1:87-94, 1996
26. ten Bokkel Huinink WW, Schreuder JE, Dubbelman R, et al: ICRF-187 protects against doxorubicin induced cardiomyopathy. Ann Oncol 3:114, 1992 (suppl 1, abstr 221)
27. Rosenfeld CS, Weisberg SR, York RM: Prevention of Adriamycin cardiomyopathy with dexrazoxane (ADR-529, ICRF-187). Proc Am Soc Clin Oncol 11:62, 1992 (abstr 74)
28. Venturini M, Michelotti A, Del Mastro L, et al: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996
29. Bonadonna G, Gianni L, Santoro A, et al: Drugs ten years later: epirubicin. Ann Oncol 4:359-369, 1993
30. Anonymous: Dexrazoxane for cardiac protection against doxorubicin. Med Lett 37:110-111, 1995
31. Basser RL, Sobol MM, Duggan G, et al: Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advances malignancy. J Clin Oncol 12:1659-1666, 1994
32. Billingham ME, Bristow MR: Evaluation of anthracycline cardiotoxicity: Predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 3:71-76, 1984
33. Jain KK, Casper ES, Geller NL, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
34. Nielsen B, Jensen JB, Dombernowsky P, et al: Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810, 1990